Medimaging Integrated Solution Inc. (MiiS) announced that its disposable cystoscopy product has received FDA 510(k) clearance. This product is a sterile, single-use endoscopic examination of the patient's lower urinary tract or adjunctive therapy, which can take pictures of the tissue of the lower urinary tract and provide real-time images for healthcare professionals to assess the damage or lesions of the tissues.

According to MiiS, there are international buyers who are interested in MiiS's micro camera module and packaging technology. The 510(k) clearance creates opportunities for licensing and marketing in global markets. 

According to Grand view research, the global disposable endoscopy market will reach US$2.08 billion by 2022, and is expected to grow at a compound annual growth rate of 16.9% from 2023 to 2030. Reducing the risk of device infections is the main factor contributing to the growth of the demand for disposable endoscopes, followed by the widespread use of minimally invasive surgeries.